Somatostatin in the treatment of patients with extra-pyramidal disorders and patients with EEG abnormalities.
The growth hormone release inhibiting hormone acts probably both as a true hypophysiotropic hormone and as a neuroregulatory substance. Neurophysiological studies have shown that somatostatin is a CNS depressant. Somatostatin might therefore be of therapeutic significance in neurological diseases. Sixteen patients with different extrapyramidal disorders and seven patients with various EEG abnormalities were tested with 2-hour somatostatin infusions and control infusions with saline. Somatostatin did not induce any improvement or deterioration of symptoms, signs, or EEG abnormalities in any patient.
D000328:Adult; D000368:Aged; D001480:Basal Ganglia Diseases / Q000188:drug therapy*; D001932:Brain Neoplasms / Q000150:complications; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D004422:Dystonia Musculorum Deformans / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy; D013004:Somatostatin / Q000627:therapeutic use*; D014653:Vascular Headaches / Q000188:drug therapy
D013004:Somatostatin